ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,133.92
      -0.09%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Eledon Pharmaceuticals Inc (ELDN)

      7. Eledon Pharmaceuticals Inc (ELDN) News

      ELDN

      Eledon Pharmaceuticals (ELDN)

      Eledon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ELDN
      DateTimeSourceHeadlineSymbolCompany
      06/14/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
      06/14/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
      06/14/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
      06/14/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
      06/06/20244:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELDNEledon Pharmaceuticals Inc
      06/06/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELDNEledon Pharmaceuticals Inc
      06/03/20244:01PMGlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/30/20244:25PMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/30/20244:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/24/20244:02PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
      05/15/20247:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
      05/13/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/09/20247:30AMGlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/09/20247:00AMGlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/07/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/07/20247:05AMGlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
      05/07/20247:00AMGlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
      03/28/20244:01PMGlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
      03/25/20244:56PMGlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
      03/21/202410:31AMGlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
      02/14/20243:35PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELDNEledon Pharmaceuticals Inc
      02/14/20243:01PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
      02/13/20247:01PMGlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
      01/04/20244:40PMGlobeNewswire Inc.Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookNASDAQ:ELDNEledon Pharmaceuticals Inc
      12/04/20236:00PMGlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
      11/29/20234:05PMGlobeNewswire Inc.Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
      11/09/20235:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
      11/09/20234:01PMGlobeNewswire Inc.Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
      11/08/20234:05PMGlobeNewswire Inc.Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
      11/02/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:ELDN